Table 2 Comparison of patient characteristics between remission and non-remission patients after 2 weeks of tacrolimus administration
Whole tacrolimus | Remission at 2 weeks | Non-remission at 2 weeks | p value |
|---|---|---|---|
(N = 87) | (N = 35) | (N = 52) | |
Female/male | 16 (46%)/19 (54%) | 23 (44%)/29 (56%) | 0.53 |
Age (years) | 36 (23–54) | 42 (28–50) | 0.42 |
Disease duration (years) | 4.0 (1.0–9.2) | 2.7 (1.1–7.0) | 0.75 |
Disease type: extensive/left-sided | 31 (89%)/4 (11%) | 40 (77%)/12 (23%) | 0.14 |
Body mass index | 19.4 (16.4–22.5) | 19.6 (17.0–22.2) | 0.77 |
Lichtiger index | 13 (12–14) | 13 (12–15) | 0.81 |
Endoscopic score (UCEIS) | 6 (5–7) | 6 (4–8) | 0.03 |
Hemoglobin (g/dL) | 10.3 (10.0–12.7) | 11.8 (9.5–13.1) | 0.44 |
Albumin (g/dL) | 3.2 (2.7–3.7) | 3.3 (2.6–3.7) | 0.85 |
C-reactive protein (mg/dL) | 3.8 (0.9–10.2) | 3.1 (1.6–7.6) | 0.96 |
Erythrocyte sedimentation rate (mm/h) | 48 (30–83) | 54 (33–75) | 0.93 |
Creatinine (mg/dL) | 0.7 (0.6–0.8) | 0.7 (0.6–0.8) | 0.92 |
Corticosteroid refractory/dependent | 23 (66%)/12 (34%) | 43 (83%)/9 (17%) | 0.06 |
Biologic agent naive | 28 (80%) | 33 (64%) | 0.08 |
Intravenous tacrolimus | 30 (86%) | 35 (67%) | 0.04 |
Decrease of Lichtiger index ≥ 3 points by day 3 | 21 (60%) | 11 (21%) | < 0.01 |
response at 1 week (LI decrease by 3 and less than 10) | 32 (91%) | 18 (35%) | < 0.01 |
Tacrolimus concentration ≥ 10 ng/ml at day 1 | 21 (60%) | 26 (50%) | 0.24 |
Tacrolimus concentration ≥ 10 ng/ml at day 3 | 31 (89%) | 42 (81%) | 0.25 |
Adverse events | 10 (29%) | 8 (15%) | 0.11 |